Guanidyl-modified albumin conjugates

By modifying albumin guanidine group, the endocytosis of albumin conjugates by tumor cells is enhanced, and the problem of low bioavailability of albumin coupled drugs is solved, which significantly improves the inhibitory activity and stability of tumor cells, and achieves more Strong anti-tumor effect.

CN118924910APending Publication Date: 2024-11-12NATURAL MEDICINE INST OF ZHEJIANG YANGSHENGTANG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310535765.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-12
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Albumin-coupled drugs have limited bioavailability due to the blocking effect of cell membranes on charged macromolecules, which in turn reduces the inhibitory activity on tumor cells.

Method used

By modifying albumin guanidine group, the endocytosis of albumin conjugates by tumor cells is enhanced, forming guanidine group modified albumin conjugates, and the endocytosis efficiency is improved using different guanidine group modification groups and the number of modifications.

Benefits of technology

It significantly enhances the inhibitory activity of albumin conjugates on tumor cells, improves anti-tumor properties and stability, and shows a stronger tumor-inhibiting effect compared with traditional albumin conjugates.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924910A_ABST
    Figure CN118924910A_ABST
Patent Text Reader

Abstract

The invention relates to a guanidyl modified albumin conjugate, in particular to a compound shown in a formula I or pharmaceutically acceptable salt thereof, a method for preparing the compound or the pharmaceutically acceptable salt thereof, a composition containing the compound or the pharmaceutically acceptable salt thereof, and a preparation method of the compound or the pharmaceutically acceptable salt thereof. It also relates to the use of the compound or a pharmaceutically acceptable salt thereof for the treatment of a disease or condition. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of pharmaceutical chemistry, and specifically relates to a compound represented by formula I or a pharmaceutically acceptable salt thereof, a method for preparing the compound or a pharmaceutically acceptable salt thereof, a composition containing the compound or a pharmaceutically acceptable salt thereof, and use of the compound or a pharmaceutically acceptable salt thereof for treating a disease or condition. Background Art

[0002] Human serum albumin (HSA, albumin or Alb) is the most abundant protein in plasma, accounting for about 40%-60% of the total protein in plasma. The concentration of human serum albumin in human blood is 35-50g / L, and the half-life is 19 days. It is composed of 585 amino acids and has a molecular weight of 66439Da. HSA can transport a variety of substances in the body, including fatty acids, metal ions and amino acids, which lays the foundation for the function of HSA in drug delivery. At the same time, HSA also has the advantages of good biocompatibility, stability, drug delivery ability, targeting, long half-life and availability, which makes the application of HSA as a drug carrier gain great attention.

[0003] So far, albumin drugs are mainly divided into albumin-conjugated drugs (covalent and non-covalent binding), albumin-based recombinant fusion drugs, albumin-bound prodrugs and albumin drug nanoparticles. Albumin drugs currently in the research stage include methotrexate albumin conjugate (MTX-HSA), doxorubicin and albumin conjugate DOXO-HSA, folic acid (FA) modified gemcitabine (Gem, Gemcitabine) and albumin conjugate FA-HSA-Gem, albumin and MMAE conjugate connected by a dipeptide linker Alb-VC-MMAE, etc.

[0004]

[0005] Although albumin can significantly reduce the dosage and cycle of drug delivery as a broad-spectrum drug delivery carrier, its weak efficacy still limits its effectiveness. The delivery of drugs by albumin-conjugated drugs will reduce protein uptake due to the blocking effect of cell membranes on charged macromolecules, resulting in limited bioavailability. Therefore, it is speculated that the activity of albumin conjugates will be limited by insufficient drug endocytosis, thereby reducing bioavailability.

[0006] Therefore, it is necessary to further improve the internalization efficiency of albumin-conjugated drugs. Summary of the invention

[0007] The inventor surprisingly found that the albumin conjugate modified with guanidine can enhance the endocytosis of the albumin conjugate by tumor cells, thereby enhancing the inhibitory activity on tumor cells. The inventor further found the relationship between different guanidine modification groups and modification amounts and endocytosis enhancement. Based on this discovery, the present invention is completed. Therefore, the present invention relates to the following aspects:

[0008] One aspect of the present invention provides a compound represented by formula I or a pharmaceutically acceptable salt thereof,

[0009]

[0010]

[0011] in and n are as defined in the present invention.

[0012] Another aspect of the present invention also provides a method for preparing the compound of the present invention or a pharmaceutically acceptable salt thereof, comprising:

[0013]

[0014] 1) reacting the compound represented by formula a with albumin to obtain the compound represented by formula b;

[0015] 2) reacting the compound represented by formula b with the compound represented by formula e to obtain the compound represented by formula I;

[0016] in and R1 are as defined in the present invention.

[0017] In the method, the reaction of step 1) allows the compound of formula a to couple to the thiol group in albumin, and the reaction of step 2) allows the carbonyl group adjacent to R1 in the compound of formula e to couple with the amino group in albumin of the compound of formula b to form an amide bond.

[0018] In certain embodiments, the method described herein further comprises:

[0019] reacting the compound represented by formula c with the compound represented by formula d to obtain the compound represented by formula e;

[0020]

[0021] wherein R1 is as defined in the present invention.

[0022] Another aspect of the present invention also provides a pharmaceutical composition comprising at least one compound of the present invention or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. In certain embodiments, the compound or a pharmaceutically acceptable salt thereof is present in a therapeutically effective amount.

[0023] Another aspect of the present invention also provides the use of the compound of the present invention or its pharmaceutically acceptable salt in the preparation of a drug for the treatment of a disease or condition. In certain embodiments, the disease or condition is selected from tumors, infectious diseases and metabolic diseases. In certain embodiments, the disease or condition is cancer or inflammation. In certain embodiments, the disease or condition is selected from blastoma, sarcoma and hematological diseases. In certain embodiments, the cancer is selected from: leukemia, breast cancer, squamous cell carcinoma, lung cancer, peritoneal cancer, liver cancer, gastric cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, bladder cancer, urethral cancer, breast cancer, intestinal cancer, uterine cancer, salivary gland cancer, kidney cancer, prostate cancer, vulvar cancer, thyroid cancer, anal cancer, penis cancer, melanoma, multiple myeloma, lymphoma; lymphoid tumors, brain cancer, gallbladder cancer, esophageal cancer, bile duct cancer and head and neck cancer.

[0024] definition

[0025] As used herein, the term "albumin" is a common human serum albumin (HSA, albumin or Alb), which is the most abundant protein in human plasma. In addition to a large amount of glutamic acid, lysine and arginine, albumin also contains 35 cysteines to form 17 disulfide bonds. Structurally, albumin consists of three homologous domains I, II and IV. Each domain is further divided into two subdomains A and B, with 6 and 4 α-helices, respectively. The terms "albumin", "HSA" or "Alb" involved in the present invention have the same meaning and refer to human serum albumin.

[0026] As used herein, the term "cytotoxin" refers to molecules that are toxic to cancer cells when released therein. A cytotoxin of particular interest in the present invention is methyl auristatin E (MMAE).

[0027] As used herein, the term "albumin-conjugated drug" refers to a product formed by coupling a cytotoxin to an albumin molecule via a linker. The compound of the present invention, i.e., the compound of formula I, may also be referred to as an albumin-conjugated drug or an albumin conjugate.

[0028] As used herein, the term "about" may be understood to be within + / -10%, + / -9%, + / -8%, + / -7%, + / -6%, + / -5%, + / -4%, + / -3%, + / -2%, + / -1%, + / -0.5%, + / -0.4%, + / -0.3%, + / -0.2%, + / -0.1% of the stated value. Unless otherwise apparent from the context, all numerical values ​​provided herein are modified by the term "about".

[0029] As used herein, the term "salt" refers to salts that retain the biological effectiveness and properties of a compound, and they are biologically or otherwise desirable for use in medicine. The term "salt" in the present invention generally refers to pharmaceutically acceptable salts. In many cases, the compounds disclosed herein are capable of forming acid and / or base salts by virtue of the presence of amino and / or carboxyl groups or similar groups. Pharmaceutically acceptable acid addition salts may be composed of inorganic acids and organic acids. Inorganic acids from which salts may be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts may be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Pharmaceutically acceptable base addition salts may be composed of inorganic bases and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; ammonium, potassium, sodium, calcium, and magnesium salts are particularly preferred. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically, for example, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. Many such salts are known in the art, as described in WO87 / 05297, Johnston et al., published September 11, 1987 (incorporated herein in its entirety by reference).

[0030] Abbreviations / acronyms

[0031] Alb (albumin): albumin;

[0032] BGA (4-Biguanidinobenzoic acid): 4-Biguanidinobenzoic acid;

[0033] BA (Benzoic acid)

[0034] DIPEA (N,N-Diisopropylethylamine): diisopropylethylamine;

[0035] DMAC (Dimethylacetamide): N,N-dimethylacetamide;

[0036] DMF (N,N-Dimethylformamide): N,N-dimethylformamide;

[0037] DMSO (Dimethyl Sulphoxide): dimethyl sulfoxide;

[0038] DXO (Doxorubicin): Doxorubicin;

[0039] FA (Folic acid): folic acid;

[0040] GA(4-Guanidinobenzoic acid): p-Guanidinobenzoic acid;

[0041] Gem(Gemcitabine): Gemcitabine;

[0042] HSA (Human serum albumin): human serum albumin;

[0043] MMAE (Monomethyl auristatin E): Monomethyl auristatin E;

[0044] MTX(Methotrexate): methotrexate;

[0045] PBS (Phosphate buffer solution): Phosphate buffered saline solution

[0046] TEA (Triethylamine): Triethylamine

[0047] The pharmaceutical composition described herein comprises the compound of formula I of the present invention or a pharmaceutically acceptable salt thereof, and a conventional pharmaceutical carrier or excipient. The pharmaceutical composition can be administered, for example, orally or parenterally, such as by intravenous injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, and the like.

[0048] As used herein, the term "effective amount" refers to an amount sufficient to achieve the desired therapeutic effect, for example, an amount to achieve a reduction in symptoms associated with the disease being treated.

[0049] It should also be noted that the dosage and method of use of the compounds of the present invention depend on many factors, including the patient's age, weight, gender, natural health, nutritional status, activity strength of the compound, time of administration, metabolic rate, severity of the disease, and the subjective judgment of the treating physician. The preferred dosage is between 0.001-1000 mg / kg body weight / day.

[0050] Advantageous Effects of the Invention

[0051] The present invention provides a compound (albumin conjugate) as shown in formula I, wherein the albumin is modified by guanidine or biguanidine. Such guanidine-modified albumin conjugate can enhance the endocytosis of tumor cells to the albumin conjugate, thereby enhancing the inhibitory activity of the albumin conjugate on tumor cells.

[0052] The albumin conjugate modified with a guanidine group provided by the present invention exhibits excellent anti-tumor properties and stability, and exhibits a stronger tumor-suppressing effect in vivo compared with a traditional albumin conjugate (Alb-VC-MMAE). BRIEF DESCRIPTION OF THE DRAWINGS

[0053] Figure 1 The mass spectrometry results of the albumin conjugate IA-IF prepared in the embodiment of the present invention are shown;

[0054] Figure 2 The SEC test results of the albumin conjugate IA-IF prepared in the embodiment of the present invention are shown;

[0055] Figure 3 The inhibitory activity of the albumin conjugate IA-IF prepared in the embodiment of the present invention on tumor cells is shown;

[0056] Figure 4 The particle size distribution of albumin conjugate 1 (AVM), IC and ID prepared in the examples of the present invention is shown;

[0057] Figure 5 The thermal stability test results of albumin conjugates 1 (AVM), IC and ID prepared in the examples of the present invention are shown;

[0058] Figure 6 The circular dichroism spectra detection results of albumin conjugate 1 (AVM) and ID prepared in the examples of the present invention are shown;

[0059] Figure 7 The stability test results of the albumin conjugate ID prepared in the embodiment of the present invention in PBS and plasma are shown;

[0060] Figure 8 The figure shows the fluorescence images taken by confocal laser scanning microscope after SKOV3 cells were treated with albumin conjugate 1 (AVM) and ID prepared in the example of the present invention;

[0061] Fig. 9 The flow cytometry quantitative analysis results of albumin conjugate 1 (AVM) and ID prepared in the examples of the present invention are shown;

[0062] Fig.10 The experimental results of cell cycle and cell apoptosis after the albumin conjugate ID prepared in the embodiment of the present invention was treated with the SKOV3 cell line;

[0063] Fig.11 The anti-tumor effects of albumin conjugates 1 (AVM) and ID prepared in the examples of the present invention in mice are shown;

[0064] Fig.12Shown are the results of tumor histopathology experiments in mice bearing xenografts of NCI-N87 cells. DETAILED DESCRIPTION

[0065] Embodiments of the present invention will be described in detail below in conjunction with the accompanying drawings and examples, but it will be appreciated by those skilled in the art that the following drawings and examples are only used to illustrate the present invention, rather than to limit the scope of the present invention. Various objects and advantages of the present invention will become apparent to those skilled in the art based on the following detailed description of the accompanying drawings and preferred embodiments.

[0066] Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art. Unless otherwise specified, the reagents used in the examples of the present invention are commercially available.

[0067] Example 1: Synthesis of albumin conjugate IA-IF

[0068]

[0069] (1) Buffer preparation

[0070] Preparation of 1× PBS:

[0071] Take 8.00g of sodium chloride, 0.20g of potassium chloride, 1.42g of disodium hydrogen phosphate and 0.27g of potassium dihydrogen phosphate, dissolve them in 1L of deionized water, stir and dissolve at room temperature, adjust the pH to 7.40 with 2M dilute hydrochloric acid, then filter and sterilize it with a 0.22μm microporous filter membrane, bottle it and place it at 4°C for use.

[0072] Preparation of Buffer-A:

[0073] Take 5.93g of sodium dihydrogen phosphate, 23.00g of disodium hydrogen phosphate and 475.70g of ammonium sulfate, dissolve them in 2L of deionized water, stir and dissolve at room temperature, adjust the pH to 7.40 with 2M dilute hydrochloric acid, filter and sterilize with a 0.22μm microporous filter membrane, bottle and place at 4°C for use.

[0074] Preparation of Buffer-B:

[0075] Take 0.59 g of sodium dihydrogen phosphate, 2.30 g of disodium hydrogen phosphate and 250 mL of isopropanol, dissolve them in 1 L of deionized water, stir and dissolve at room temperature, adjust the pH to 7.4 with 2 M dilute hydrochloric acid, filter and sterilize with a 0.22 μm microporous filter membrane, bottle and place at 4°C for use.

[0076] Preparation of carbonate buffer solution (CBS solution):

[0077] Weigh 1.59 g of Na2CO3 and 2.94 g of NaHCO3, add distilled water to make up to 1000 mL, adjust the pH to 9.6 with 2 M dilute hydrochloric acid, then filter and sterilize with a 0.22 μm microporous filter membrane, bottle and store at 4°C.

[0078] (2) Preparation of albumin conjugate 1 (Alb-VC-MMAE, AVM)

[0079] The albumin solid powder (purchased from Zhejiang Hisun Pharmaceutical Group Co., Ltd., 1.00eq) was weighed and placed in a clean eggplant-shaped bottle, and the 1×PBS buffer prepared above was used to prepare a 10mg / mL reaction solution, and the mass (2.40eq) required for the small molecule raw material Mal-VC-MMAE (purchased from Beijing Coupling Technology Co., Ltd.) was calculated, and it was dissolved in an organic solvent (DMAC, N,N-dimethylacetamide, 80μL) with a total reaction solution volume of 8%. Under slow stirring at room temperature, the small molecule raw material Mal-VC-MMAE solution was slowly dripped into the albumin solution with a pipette, and the reaction was maintained for 4-8h. Next, the reaction was terminated and the unreacted raw material Mal-VC-MMAE was blocked. The small molecule NAC (N-acetylcysteine, 4.80 eq) with a reducing thiol group was weighed and dissolved in an aqueous solution (1.00 mg / mL), and was slowly added dropwise to the reaction solution using a pipette. The reaction was continued for 30 min to terminate the reaction and block the unreacted raw material Mal-VC-MMAE.

[0080] After the reaction solution was concentrated to 5 mL using an ultrafiltration tube, the unreacted albumin in the reaction solution was removed using GE's AKTA Purifier and hydrophobic interaction chromatography column Phenyl-50 mL, and the buffers used were the above-configured Buffer-A and Buffer-B. After the obtained reaction solution was ultrafiltered and concentrated, the small molecules in the reaction solution were removed again using GE's AKTA Purifier and molecular exclusion chromatography column G25-25 mL. The collected solution was filtered and sterilized using a 0.22 μm microporous filter membrane and packaged to obtain albumin conjugate 1, which was stored at -80°C for future use.

[0081] (3) Preparation of Intermediate 2

[0082] Add p-guanidine benzoic acid (26.88 mg, 0.15 mmol) to a 10 mL eggplant-shaped bottle, add 1 mL of anhydrous DMF to disperse it into the solution to form a turbid liquid. Under magnetic stirring at 300 rpm, add TEA (41 μL, 0.294 mmol) and isobutyl chloroformate (36 μL, 0.285 mmol) successively, react at room temperature for 1 hour, transfer to a 4°C refrigerator and place for 1 hour. Place the reaction solution in a centrifuge, centrifuge at 4000 rpm for 15 minutes, take the supernatant and pre-cool it in a 4°C refrigerator for later use.

[0083] (4) Preparation of Intermediate 3

[0084] Add p-biguanidinobenzoic acid (33.18 mg, 0.15 mmol) to a 10 mL eggplant-shaped bottle, add 1 mL of anhydrous DMF to disperse it into the solution to form a turbid liquid. Under magnetic stirring at 300 rpm, add TEA (41 μL, 0.294 mmol) and isobutyl chloroformate (36 μL, 0.285 mmol) successively, react at room temperature for 1 hour, transfer to a 4°C refrigerator and place for 1 hour. Place the reaction solution in a centrifuge, centrifuge at 4000 rpm for 15 minutes, take the supernatant and pre-cool it in a 4°C refrigerator for later use.

[0085] (5) Preparation of intermediate 4

[0086] Benzoic acid (18.32 mg, 0.15 mmol) was added to a 10 mL eggplant-shaped bottle, and 1 mL of anhydrous DMF was added to disperse it into the solution to form a turbid liquid. TEA (41 μL, 0.294 mmol) and isobutyl chloroformate (36 μL, 0.285 mmol) were added successively under magnetic stirring at 300 rpm, and the mixture was reacted at room temperature for 1 hour, and then transferred to a 4°C refrigerator for 1 hour. The reaction solution was placed in a centrifuge and centrifuged at 4000 rpm for 15 minutes, and the supernatant was pre-cooled in a 4°C refrigerator for later use.

[0087] (6) Preparation of albumin conjugate IA-IF

[0088] Take 3 mL of PBS solution of albumin conjugate 1 with a concentration of 2 mg / mL, replace it with CBS solution with ultrafiltration at pH = 9.6, add intermediate 2 (19.50 μL) synthesized and stored in the above to the reaction solution under slow stirring, and react for 4-6 hours. Use GE's AKTA Purifier and molecular exclusion chromatography column G25-25 mL to remove small molecules in the reaction solution, filter the collected solution with a 0.22 microporous filter membrane for sterilization and package it to obtain albumin conjugate IA, which is stored at -80°C for use.

[0089] The synthesis and purification methods of albumin conjugates IC and IE were similar to those of albumin conjugate IA, except that intermediate 2 was replaced by intermediates 3 (19.50 μL) and 4 (19.50 μL), respectively.

[0090] The synthesis and purification methods of albumin conjugates IB, ID and IF were similar to those of albumin conjugate IA, except that the amounts of intermediate 2 (39.00 μL), intermediate 3 (39.00 μL) and intermediate 4 (39.00 μL) were different.

[0091] Experimental Example 1: Determination of the concentration of albumin conjugate

[0092] The concentrations of all albumin conjugates prepared in Example 1 above were determined by the BCA (protein quantification kit) method, and the kit was a Thermo BCA kit (including a standard protein solution: 2000.00 μg / mL and working solutions A and B). The specific operation is to first gradually dilute the BCA kit standard protein solution with PBS to obtain protein solutions: A (2000.00 μg / mL), B (1500.00 μg / mL), C (1000.00 μg / mL), D (750.00 μg / mL), E (500.00 μg / mL), F (250.00 μg / mL), G (125.00 μg / mL), H (25.00 μg / mL), I (0 μg / mL). Then prepare the colorimetric solution, and prepare the working solutions A and B in the kit according to 50:1 to obtain the colorimetric solution. Add 200 μL of the prepared colorimetric solution to each well of a 96-well plate. Then, 25 μL of the prepared protein solution and the sample to be tested were added to a 96-well plate with a colorimetric solution, and incubated in a 37°C incubator for 30 min. The OD value (optical density) was measured at 570 nm using an ELISA reader, and a standard curve was drawn based on the measured value to obtain the concentration of the sample to be tested.

[0093] Experimental Example 2: Mass spectrometry

[0094] The IA-IF mass spectra of the albumin conjugate prepared in Example 1 were determined using a 5800TOF / TOF (AB Sciex, Framingham, MA, 01701, USA) with a MALDI-TOF source, with the following settings: the calibration batch was run as an internal calibration with a mass tolerance of ±800ppm. The minimum signal-to-noise ratio was 4 and the maximum outlier error was 500ppm. The following reference masses were used: 33216 m / z (BSA++) and 66431m / z (BSA+), the mass range of the acquisition method was 10000 to 100000m / z, the focus mass was 60000m / z, the laser intensity was set to 7500, and each spectrum had a total of 4000 emissions. The spectra were processed using baseline subtraction (peak width 30). Three times the minimum signal-to-noise ratio was applied to peak detection, and the local noise window width was 400m / z. The resolution was 200m / z.

[0095] Test results such as Figure 1 As shown. The number of small molecules for modifying albumin connected in albumin conjugates IA-IF was calculated according to the mass spectrometry detection results. The results showed that the number of GA connected in albumin conjugate IA was about 19, the number of GA connected in albumin conjugate IB was about 38, the number of BGA connected in albumin conjugate IC was about 10, the number of BGA connected in albumin conjugate ID was about 15, the number of BA connected in albumin conjugate IE was about 13, and the number of BA connected in albumin conjugate IF was about 38.

[0096] Experimental Example 3: Determination of the degree of polymerization of albumin conjugate IA-IF by size exclusion chromatography (SEC)

[0097] The degree of polymerization of the albumin conjugate IA-IF prepared in Example 1 was determined using the SEC-HPLC method. The chromatographic column used was a TSKgel UP-SW3000 analytical column (4.6 mm×150 mm, Tosoh Corporation, Tokyo, Japan), the mobile phase was a 40 mmol / L sodium phosphate solution, the elution method was isocratic elution, and the chromatographic peaks were collected at a wavelength of 280 nm.

[0098] The results are as follows Figure 2 As shown, the results prove that the single existence form of the albumin conjugate IA-IF prepared in Example 1 exceeds 95%.

[0099] Experimental Example 4: In vitro cytotoxicity assay

[0100] The cells were plated at approximately 5 × 10 3Cells were seeded at a cell density of 100 μL of serum cell culture medium in a 96-well plate and incubated. One day after inoculation, all test albumin conjugates were diluted from the highest concentration in a 3-fold gradient and added to the supernatant of the well plate. After 4 days of culture under growth conditions, the culture plate was removed from the incubator and equilibrated at room temperature for 30 minutes. 100 μL of CellTiter Glo luminescent solution (Promega, Cat.No G7570) was added to each well. After mixing at 650 rpm for 5 minutes, the well plate was placed at room temperature for 10 minutes. Finally, The luminescence intensity was measured on the Navigator system with a measurement time of 1 s per well.

[0101] The tumor cell inhibition curve was drawn according to the luminescence intensity, and the inhibitory activity of the albumin conjugate on tumor cells (EC 50 value), the result is Figure 3 The results showed that the EC of albumin conjugate 1 (AVM) and IA-IF in SKBR3 human breast cancer cell line 50 The values ​​were 77.61, 72.25, 43.55, 40.38, 23.39, 107.20, and 114.50 nM, respectively. In the SKOV3 human ovarian cancer cell line, the EC values ​​of albumin conjugate 1 (AVM) and IA-IF were 50 The values ​​were 286.00, 242.00, 130.90, 115.60, 71.78, 357.10, and 456.60 nM, respectively. In the NCI-N87 human gastric cancer cell line, the EC values ​​of albumin conjugate 1 (AVM) and IA-IF were 50 The values ​​are 376.10, 322.60, 233.50, 163.90, 98.09, 524.80, and 541.20 nM, respectively.

[0102] The above experimental results show that the use of guanidine-containing group-modified albumin-conjugated drugs can effectively enhance endocytosis through hydrogen bonding, thereby enhancing anti-tumor activity at the cellular level. The activity of BGA modification is better than that of GA modification, and cytotoxicity can also be improved by increasing the number of modifications.

[0103] Experimental Example 5: Particle Size Measurement

[0104] Dynamic light scattering (DLS) was performed on the albumin conjugate 1 (AVM), IC and ID using a 660 nm laser on UNcle running client software V5.03. The measurement volume of each sample to be tested was 9 μL, which was filled into the sample loader. Each measurement was averaged four times, each acquisition was 5 s, and the laser power was automatically attenuated at the beginning of each acquisition. The size analysis was performed using the distribution fitting of the preset general analysis model.

[0105] Particle distribution of albumin-conjugated drug 1 (AVM), IC and ID Figure 4 As shown. The results show that although there is aggregation among the three in the light intensity distribution, their mass distribution is relatively uniform (Pk 1mass≈100%). The particle diameters of albumin-conjugated drug 1 (AVM), IC and ID are 7.27nm, 8.54nm and 9.20nm (Pk 1mode Dia. (nm)), respectively, indicating that the guanidine modification of AVM does not significantly change its particle size and its distribution is uniform.

[0106] Experimental Example 6: Thermal Stability Determination

[0107] Dynamic light scattering (DLS) was performed on the thermal stability of albumin conjugates 1 (AVM), IC and ID on UNcle running client software V5.03. A linear temperature increase from 15°C to 95°C was performed at a rate of 0.3°C / min, and the measurement volume of each sample was 9 μL, which was filled into the sample loader. The samples were irradiated with UV filter and blue filter, and the incubation time was 120 seconds. Data analysis was performed using UNcle analysis software V5.03. The change of intrinsic fluorescence (using 266nm laser excitation) with temperature was monitored by analyzing the center of gravity mean (BCM) between 300-430nm. And the change of static light scattering was detected by measuring the intensity of the peaks at 266 and 473nm. The melting temperature (Tm) and aggregation temperature (Tagg) of the albumin conjugate were obtained from the maximum gradient and temperature trajectory of the BCM. The results are shown in Figure 5 .

[0108] The results showed that the T of albumin conjugate 1 (AVM), IC and ID m The values ​​were 74.6℃, 74.3℃ and 71.5℃ respectively. With the increase of the number of biguanidine modifications, T m The Tagg values ​​of albumin conjugates 1 (AVM), IC, and ID were 65.3°C, 63.9°C, and 53.9°C, respectively. As the number of modifications increased, Tagg The T values ​​of the three conjugates decreased slightly. agg Value and T m The values ​​are all higher than room temperature, indicating that they have good stability.

[0109] Experimental Example 7: Circular Dichroism Spectrum Measurement

[0110] Circular dichroism (CD) spectra were recorded by a MOS-450 (Biologic, Claix, Frence) CD spectrometer. The samples were diluted to 11 μM in PBS and measured in a rectangular quartz cell (path length 1 mm) sealed with a polytetrafluoroethylene stopper. CD spectra were recorded in the range of 260 nm to 180 nm with a step size of 1 nm and a sampling time of 0.5 s. The test results are shown in Figure 6 shown.

[0111] This experiment verified the effects of thiol conjugation and guanidation modification on the secondary spatial morphology of albumin. The results showed that the spatial structure of albumin conjugates 1 (AVM) and ID did not change significantly compared with Alb, indicating that thiol conjugation and / or guanidation modification of albumin in the conjugate would not affect the spatial structure of albumin.

[0112] Experimental Example 8: Plasma stability experiment

[0113] In order to determine the stability of the albumin conjugate ID prepared in the embodiment of the present invention in human plasma and PBS, the free payload MMAE was dissolved in 50% human plasma and PBS to prepare standard samples, and the preparation of the test sample was the same as that of the standard. Both samples were incubated at 37°C for 10 days. According to the MMAE standard curve established using LC-MS, the concentration of the total free payload MMAE released from the albumin conjugate was determined at different time points.

[0114] Test results see Figure 7 The results showed that the albumin conjugate ID prepared in the embodiment of the present invention can remain stable in PBS buffer and 50% human plasma at 37°C.

[0115] Experimental Example 9: Laser Confocal Localization Experiment

[0116] SKOV3 cells were grown in DMEM and RPMI-1640 medium at 37°C in an environment with 5% CO2, and the medium was supplemented with 10% fetal bovine serum and 0.1% penicillin-streptomycin. The cell density of SKOV3 cells was approximately 3×10 4Cells were treated with FITC-labeled albumin conjugate (600 nM) and incubated for 24 h. The cells were briefly washed with PBS and treated with Lyso Tracker and Hoechst Tracker in the culture medium. The cells were washed three times with PBS and placed in 1 mL of PBS solution. Fluorescence images were taken using a confocal laser scanning microscope (Nikon ECLIPSE Ti, Nikon, Japan). The results are shown in Figure 8 .

[0117] The results showed that after treatment with albumin conjugate 1 (AVM), the cells had a weak intracellular fluorescence intensity, indicating that they had relatively poor endocytic ability. After treatment with albumin conjugate ID modified with biguanide BGA, the intracellular fluorescence increased, indicating that the endocytic ability of the albumin conjugate was significantly enhanced.

[0118] Experimental Example 10: Flow cytometry quantitative experiment

[0119] SKOV3 cells were grown in DMEM and RPMI-1640 medium at 37°C in an environment with 5% CO2, and the medium was supplemented with 10% fetal bovine serum and 0.1% penicillin-streptomycin. The cell density of SKOV3 cells was approximately 1×10 5 Cells / well were cultured overnight in culture medium, treated with FITC-labeled albumin conjugate 1 (AVM) and ID (600nM), and after 24h of incubation, the cells were briefly washed with PBS, the cell suspension was prepared with trypsin-EDTA and centrifuged, the supernatant was removed and washed three times with PBS, and the cells were placed in 200μL of PBS solution. Flow cytometry analysis was performed using BD FACSAria II, and the analysis results are shown in Fig. 9 .

[0120] The results showed that under the same conditions, the intracellular fluorescence intensity of cells treated with FITC-labeled albumin conjugate ID (ID-FITC) was higher than that of cells treated with FITC-labeled albumin conjugate 1 (AVM-FITC) (P***=0.0009), indicating that BGA modification of albumin-conjugated drug 1 can effectively enhance its endocytosis ability and improve its bioavailability.

[0121] Experimental Example 11: Cell cycle and apoptosis experiment

[0122] In order to evaluate whether the mechanism of killing tumors by the albumin conjugate prepared in the embodiment of the present invention is consistent with the effective load, apoptosis and cell cycle experiments were performed on the albumin conjugate ID.

[0123] In order to determine the cytotoxic mechanism of the albumin conjugate prepared in the present invention, apoptosis and cell cycle analysis were performed respectively. SKOV3 cells were cultured at a rate of about 5×10 4 Cells were seeded at a density of 10 cells / well in 12-well plates and treated with different concentrations (0, 100 and 300 nM) of conjugate ID for 96 hours. Cell apoptosis and cell death were detected using Annexin V-FITC apoptosis kit (Dojindo, Japan) and propidium iodide (PI) staining on BD FACSAria II.

[0124] For cell cycle analysis, the SKOV3 cell line was treated with albumin conjugate ID for 48 h, and then bromodeoxyuridine (BrdU; Beyotime Biotechnology, Shanghai, China) was added for 20 min. Anti-BrdUrd-FITC was used to detect the synthesis of nascent DNA, and phycoerythrin (PE) staining was used to detect the total DNA content. Cell cycle analysis was measured using FACSCalibur (BD Biosciences).

[0125] The results of cell cycle and apoptosis experiments are shown in Fig.10 . MMAE is a tubulin inhibitor that causes cell cycle arrest at the G2 / M phase, leading to cell apoptosis. SKOV3 cells were treated with different concentrations of albumin conjugate ID for 96 hours, and the apoptosis rate in the PBS group was 7.33%, but for albumin conjugate ID at concentrations of 100nM and 300nM, the apoptosis rates were 13.06% and 29.67%, respectively. The apoptosis rate was significantly increased compared with the control group, indicating that albumin conjugate ID can release MMAE, thereby effectively inducing cell apoptosis. The cell cycle of albumin conjugate ID was tested, and SKOV3 cells were treated with different concentrations of albumin conjugate ID for 48 hours. The proportion of cells in the G2 / M phase of PBS and albumin conjugate ID at concentrations of 100nM and 300nM were 20.1%, 38.1%, and 53.5%, respectively. The results showed that albumin conjugate ID can effectively arrest the SKOV3 cell cycle at the G2 phase.

[0126] Experimental Example 12: In vivo anti-tumor efficacy experiment

[0127] Female BALB / c nude mice aged 6-8 weeks (purchased from SPF (Beijing) Biotechnology Co., Ltd.) were housed in an SPF animal breeding center with 3 mice per cage. Animal research followed the ARRIVE guidelines. NCI-N87 cells (approximately 1×10 7 ) were subcutaneously inoculated into mice when the tumor size was approximately 120 mm 3 or 180mm 3At the time of the study, mice carrying xenografts of NCI-N87 cells were randomly divided into four treatment groups, including a high-dose albumin conjugate ID treatment group (33 mg / kg), a low-dose albumin conjugate ID treatment group (17 mg / kg), a high-dose albumin conjugate 1 (AVM) treatment group (33 mg / kg), and a low-dose albumin conjugate 1 (AVM) treatment group (17 mg / kg), and a PBS solvent control group, which were administered through the tail vein on days 0, 4, and 7, respectively. Starting from day 0, the tumor size was measured with a digital caliper, and the general condition of the animals (mental state, activity, hair color) was observed twice a week. The equation (0.5×L×W 2 ) to calculate the tumor volume, where L and W represent the length and width of the tumor, respectively. At the end of the experiment, the mice were killed by cervical dislocation.

[0128] Results of tumor suppressor activity are given in Fig.11 . Compared with the control group (PBS group), the four treatment groups had significant tumor inhibitory effects. There was a significant difference in tumor volume between the albumin conjugate 1 (AVM) and ID high-dose treatment groups (33 mg / kg) (P**=0.0026), and 50% of the tumors in the ID group disappeared completely. At the same time, no weight loss was observed in any treatment group during the treatment period, and there was no significant difference in the body weight of the test mice between the treatment group and the control group. The results showed that albumin conjugate 1 (AVM) and ID were initially well tolerated at the administered therapeutic dose. In addition, the tumor volumes of the albumin conjugate ID and albumin conjugate 1 (AVM) treatment groups at different doses were significantly different (ID: p**=0.0016, AVM: p*=0.0333), indicating that the albumin conjugate was dose-dependent on tumor inhibition. The above studies show that albumin conjugate ID has superior anti-tumor inhibitory activity than albumin conjugate 1 (AVM).

[0129] Experimental Example 13: Histopathology Experiment

[0130] After the mice were killed in Experimental Example 11, the tumor tissues of the mice were used for pathological research. The tumor tissue samples were fixed in formalin buffer (10%) for 24 hours, transferred to ethanol (70%), and the tissues were dehydrated by ethanol solutions with increasing concentration gradients, and then treated with toluene and paraffin. Finally, the tissues embedded in the paraffin block were sliced, then stained with H&E (hematoxylin-eosin), and placed under a microscope for reading and photography. The results are shown in Fig.12 .

[0131] In the histopathological evaluation of hematoxylin and eosin (H&E) staining (tumor), the treatment groups given albumin conjugate 1 (AVM) and ID showed obvious tumor tissue necrosis compared with the control group (PBS group). Among them, the tumor tissue necrosis area in the high-dose treatment group of albumin conjugate 1 (AVM) and ID was larger than that in the low-dose treatment group. In addition, at the same dose, the tumor necrosis area in the albumin conjugate ID treatment group was also larger than that in the albumin conjugate 1 (AVM) treatment group. The above results indicate that albumin conjugate ID has superior anti-tumor inhibitory activity than albumin conjugate 1 (AVM).

[0132] The above experimental results show that the albumin conjugate containing guanidine modification prepared in the embodiment of the present invention not only exhibits good anti-tumor activity in vitro and in vivo, but also has the effect of the modifier on the activity of the albumin conjugate: BGA>GA>BA, and the activity increases with the increase in the number of connected modifiers. After guanidine modification, the albumin conjugate has a uniform particle size distribution without unstable aggregation, and has good thermal stability, and the secondary spatial structure remains basically consistent with albumin. On the other hand, in the study of its mechanism, laser confocal localization experiments show that it can be effectively transported to lysosomes, and flow cytometry proves that the modified albumin conjugate can effectively enhance endocytosis, and cell cycle and apoptosis experiments prove that its drug action mechanism is consistent with the free payload MMAE. In short, guanidinyl modification of the antibody end of the albumin conjugate can effectively enhance endocytosis and achieve better anti-tumor effects.

[0133] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.

Claims

1. A compound represented by formula I or a pharmaceutically acceptable salt thereof, in, represents albumin, R1 is guanidine or biguanide, and n is a number between 1 and 60.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein n is a number between 1 and 55, for example, 10, 13, 15, 19, 20, 25, 28, 30, 35, 38, 40, 45, 48, 55, 58.

3. The compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, wherein the compound is as shown in formula I-1, in, R1 and n are as defined in claim 1 or 2.

4. The compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from: in and n are as defined in claim 1 or 2.

5. A method for preparing a compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof, comprising: 1) reacting the compound represented by formula a with albumin to obtain the compound represented by formula b; 2) reacting the compound represented by formula b with the compound represented by formula e to obtain the compound represented by formula I; in and R1 are as defined in claim 1 or 2.

6. The method of claim 5, further comprising: reacting the compound represented by formula c with the compound represented by formula d to obtain the compound represented by formula e; Wherein R1 is as defined in claim 4.

7. A pharmaceutical composition comprising at least one compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients.

8. The pharmaceutical composition of claim 7, wherein the compound or a pharmaceutically acceptable salt thereof is present in a therapeutically effective amount.

9. Use of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 in the preparation of a medicament for treating a disease or condition, wherein the disease or condition is selected from tumors, infectious diseases and metabolic diseases. Preferably, the disease or disorder is cancer or inflammation. Preferably, wherein the disease or disorder is selected from blastoma, sarcoma and hematological disease. Preferably, the cancer is selected from the group consisting of leukemia; breast cancer; squamous cell carcinoma; lung cancer; peritoneal cancer; liver cancer; gastric cancer; pancreatic cancer; glioblastoma; cervical cancer; ovarian cancer; bladder cancer; urethral cancer; breast cancer; intestinal cancer; uterine cancer; salivary gland cancer; kidney cancer; prostate cancer; vulvar cancer; thyroid cancer; anal cancer; penile cancer; melanoma; multiple myeloma; lymphoma; lymphoid tumors; brain cancer; gallbladder cancer; esophageal cancer; bile duct cancer; and head and neck cancer.